Pfizer Japan's R&D centre reborn as RaQualia
This article was originally published in Scrip
Executive Summary
Some 18 months after announcing that it would close the facility, Pfizerhas spun out its former central research laboratories in Japan into a new stand-alone business which will develop and license a portfolio of compounds sourced from its former parent.